Cefuroxime-Induced Thrombocytopenia?

Total Page:16

File Type:pdf, Size:1020Kb

Cefuroxime-Induced Thrombocytopenia? Spontaneous cure of osteitis fibrosa cystica 757 1 Norris EH. Primary hyperparathyroidism. Arch Pathol 1946; 6 Norton JA, Aurbach GD, Marx SJ, Doppman JL. Surgical 42: 261-73. management of hyperparathyroidism. In: De Groot LJ, ed. 2 Minisola S, Romagnoli E, Scarnecchia L, et al. Parathyroid Endocrinology. Philadelphia: WB Saunders, 1989; pp 1013- Postgrad Med J: first published as 10.1136/pgmj.72.854.757 on 1 December 1996. Downloaded from storm: immediate recognition and pathophysiological con- 31. siderations. Bone 1993; 14: 703-6. 7 Brown EM, Wilson RE, Thatcher JG, Marynick SP. 3 Howard JE, Follis RH, Yendt ER, Connor TB. Hyperpar- Abnormal calcium regulated PTH release in normal athyroidism. Case report illustrating spontaneous remission parathyroid tissue from patients with adenoma. Am Jf Med due to necrosis of adenoma. J Clin Endocninol Metab 1953; 1981; 71: 565-74. 13: 997-1008. 8 Peck WW, Higgins CB, Fisher MR, et al. Hyperparathyr- 4 Frost HM. Bone remodeUling and its relationship to metabolic oidism: comparison of MR imaging with radionuclide bone disease. Springfield IL: Charles C Thomas, 1973. scanning. Radiology 1987; 163: 415-20. 5 Aurbach GD, Marx SJ, Spiegal AM. Parathyroid hormone, 9 Lumb GA, Stanbury SW. Parathyroid function in human calcitonin and calciferols. In: Wilson JD, Foster DW, eds, vitamin D deficiency and vitamin D deficiency in primary Williams textbook of endocrinology. Philadelphia: WB Saun- hyperparathyroidism. Am J Med 1974; 56: 8335. ders, 1985. Cefuroxime-induced thrombocytopenia? Peter Aitken, SMN Zaidi Summary admission. Investigations included full blood We present the case of a 77-year-old man count, erythrocyte sedimentation rate, mid- who became thrombocytopenic whilst stream urine and urinary electrolytes, liver treated parenterally with cefuroxime in function tests, calcium, glucose, thyroid func- the absence of proven infection and re- tion tests, VDRTIPA, three sets of blood covered when the cefuroxime was discon- cultures, malarial parasites, a chest X-ray and tinued. an electrocardiogram. The significant preliminary result was Keywords: cefuroxime, thrombocytopenia growth ofa Staphylococcus species (unspecified) in one blood culture bottle. We commenced cefuroxime 750 mg tid parenterally. We re- Since 1966 there have been a number of case peated the full blood count on days one and reports suggesting a link between cephalospor- three of cefuroxime therapy and noted the in therapy and blood dyscrasias, especially platelet count to have fallen to 92 x 109/1. We http://pmj.bmj.com/ thrombocytopenia.1 In each case the causal considered this to be due to presumed infec- link remains unproven because of the presence tion or a side-effect of medication. On day five of confounding variables and the ethical posi- of cefuroxime therapy we received the final tion that precludes re-exposure of the sensitive microbiological report on the blood culture individual to confirm the cause and effect. An identifying the organism as Staphylococcus immunological mechanism has been described epidermidis, a contaminant skin commensal. in cefotetan-induced thrombocytopenia where We stopped cefuroxime and repeated the full on September 24, 2021 by guest. Protected copyright. potent IgG-cefotetan-dependent antiplatelet blood count days later, finding that the platelet antibodies were detected in the patient's count had risen to 164 x 109/l. Nine days later serum.2 An animal model in the dog has also it was 325 x 109/1. The diagnosis was now a been described.3 severe depressive episode. A course of electro- convulsive therapy was started on the day after Case report A 77-year-old man known to suffer from mild Alzheimer's disease and recurrent depressive Side-effects of cefuroxime disorder was admitted with a 10-day history of increasing anxiety and agitation and worsening * hypersensitivity reactions depression. Examination revealed marked psy- * overgrowth of susceptible organisms * gastrointestinal disturbance chomotor agitation, perseverations and verbal * pseudomembranous colitis stereotypies. His cognitive functioning had * haematological parameters altered, including Department of deteriorated. He appeared physically ill with a decreased haemoglobin concentration, Psychiatry, Farnham fluctuating conscious level, tachycardia, ta- leucopenia, neutropenia Road Hospital, chypnoea and profuse sweating. He remained * positive Coombs test Guildford, Surrey apyrexial. * transient rise in liver function tests GU2 5LX, UK * pain at injection site P Aitken We diagnosed acute confusional state (delir- * very rare reports of thrombocytopenia SMN Zaidi ium ICD 10) superimposed on mild dementia precipitating a relapse of his depressive dis- Accepted 7 February 1996 order. We started haloperidol 5 mg bid on Box 1 758 Aitken, Zaidi Drugs implicated in immune Learning points thrombocytopenial Postgrad Med J: first published as 10.1136/pgmj.72.854.757 on 1 December 1996. Downloaded from * severe depressive episode can be difficult to Drug-dependent platelet-activating IgG (Fc receptor differentiate from organic pathology, especially dependent) in the elderly Unfractionated heparin, low molecular weight * many drugs are implicated in immune heparin, pentosan polysulphate, chondroitin thrombocytopenia, including many commonly sulphate. prescribed antibiotics * cefuroxime appears capable of producing a Drug-dependent increase in platelet-associated moderately severe thrombocytopenia IgG (Fab-dependent, Fc-independent, binding to glycoproteins IIb/IIIa or IblIX or both) Quinine, quinidine, vancomycin. Box 3 Drug-dependent increase in platelet-associated IgG (glycoprotein localisation unknown) Ampicillin, cephamandole, chlorpheniramine, stopping cefuroxime. He received four treat- cimetidine, diazepam, digoxin, gold, ments over two weeks; the haloperidol was hydrochlorthiazide, mianserin, 'sulfa' antibiotics, then reduced and stopped. He made a com- penicillin, ranitidine, rifampicin. plete recovery. Probable drug-induced thrombocytopenia (established by drug rechallenge or drug-dependent Discussion phase 1 assay) Acetaminophen, acetazolamide, actinomycin, Early investigative results suggested a staphy- allyl-isopropyl-acetylcarbamide, alprenolol, lococcal infection which was treated blind with aminoglutethimide, amiodarone, antazoline, cefuroxime 750 mg tid parenterally for five aspirin, carbamazepine, cephalexin, cephalothin, chlorthalidone, chlorthiazide, danazol, days. When the platelet count was noted to be desferrioxamine, desipramine, falling, other causes of thrombocytopenia were difluoromethylornithine, digitoxin, diflunisal, considered. After the final microbiology report, diphenylhydantoin, ethchlorvynol, furosemide, an infective aetiology was less likely. Through- gentamycin, imipramine, iopanoic acid, out treatment with cefuroxime the clinical state levamisole, alpha-interferon, beta-inteferon, remained unchanged, as did the neutrophilia. lidocaine, mepabromate, methicillin, minoxidil, morphine, methyldopa, nomifensine, novobiocin, This made it less likely that the patient had an paraaminosalicylic acid, phenyl butazone, undiagnosed infection that responded to ce- oxprenolol, naladixic acid, pirenzipine, furoxime. The only concomitant drug therapy procainamide, spironolactone, stibophen. was haloperidol 5 mg bid, not known to cause thrombocytopenia. In the absence of a proven Possible drug-induced thrombocytopenia (no microbiological cause and with resolution on rechallenge or in vitro testing) Apalcillin, butobarbitone, captopril, stopping the cefuroxime we believe that the chlordiazepoxide/clidinium bromide, thrombocytopenia can only have been due to chlorpropamide, clinoril, clonazepam, the cephalosporin. We considered it unethical diatrizoate, diazoxide, etretinate, fenoprofen, to submit him to rechallenge. glibenclamide, heroin, indomethacin, isoniazid, Review of the literature reports cephalospor- http://pmj.bmj.com/ levodopa, lincomycin, nitroprusside, in and penicillin antibiotics to be implicated in oxyphenbutazone, oxytetracycline, pentamidine, piroxicam, primidone, sulindac, ticlopidine, immune thrombocytopenia by a drug-depen- tobramycin, tolbutamide, tolmetin, toluene. dent increase in platelet-associated IgG. We believe this case to be the first to implicate Drugs with high incidence of mild thrombocytopenia cefuroxime directly. and positive direct platelet-associated IgG Valproic acid, amrinone. on September 24, 2021 by guest. Protected copyright. Drug-induced lupus anticoagulant syndrome and thromboembolism Procainamide. Drug-induced haemolytic-uraemic syndrome Quinine, proguanil, penicillin, ampicillin. Drug-induced immune haemolytic anaemia with thrombocytopenia Diclofenac, doxepin, glafenine, nomifensine. Box 2 1 Hull RL, Brandon D. Thrombocytopenia possibly caused 4 ABPI Data Sheet Compendium: Cefuroxime, 1995-6, by structurally related third generation cephalosporins. p 656. DICP 1991; 25: 135-6. 5 Bloom AL, Forbes CD, Thomas DP, Tiddenham EGD, 2 Christie DJ, Lennon SS, Drew RL, Swinehart CD. (editors). Acquired platelet disorders: drugs implicated in Cefotetan-induced immunologic thrombocytopenia. Br J immune thrombocytopaenia: haemostasis and thrombosis, Haematol 1988; 70: 423-6. Vol 2. London: Churchill Livingstone, 1994; pp 776-8. 3 Bloom JC, Lewis HB, Sellers TS, Deldar A. The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematoxicity in man. Toxicol Appl Pharmacol 1987; 90: 135 - 42..
Recommended publications
  • Urological Infections
    Guidelines on Urological Infections M. Grabe (chair), R. Bartoletti, T.E. Bjerklund-Johansen, H.M. Çek, R.S. Pickard, P. Tenke, F. Wagenlehner, B. Wullt © European Association of Urology 2014 TABLE OF CONTENTS PAGE 1. INTRODUCTION 8 1.1 Background 8 1.2 Bacterial resistance development 8 1.3 The aim of the guidelines 8 1.4 Pathogenesis of UTIs 8 1.5 Microbiological and other laboratory findings 9 1.6 Methodology 10 1.6.1 Level of evidence and grade of guideline recommendations 10 1.6.2 Publication history 10 1.7 References 11 2. CLASSIFICATION OF UTIs 12 2.1 Introduction 12 2.2 Anatomical level of infection 12 2.3 Grade of severity 13 2.4 Pathogens 14 2.5 Classification of UTI 14 2.6 Reference 15 3. UNCOMPLICATED UTIS IN ADULTS 15 3.1 Summary and recommendations 15 3.2 Definition 15 3.2.1 Aetiological spectrum 15 3.3 Acute uncomplicated sporadic cystitis in premenopausal, non-pregnant women 15 3.3.1 Diagnosis 15 3.3.1.1 Clinical diagnosis 15 3.3.1.2 Laboratory diagnosis 15 3.3.2 Therapy 15 3.3.3 Follow-up 16 3.4 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 16 3.4.1 Diagnosis 16 3.4.1.1 Clinical diagnosis 16 3.4.1.2 Laboratory diagnosis 16 3.4.1.3 Imaging diagnosis 16 3.4.2 Therapy 17 3.4.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 17 3.4.2.2 Severe cases of acute uncomplicated pyelonephritis 17 3.4.3 Follow-up 19 3.5 Recurrent uncomplicated UTIs in premenopausal women 20 3.5.1 Diagnosis 20 3.5.2 Antimicrobial treatment and prevention 20 3.5.2.1 Antimicrobial prophylaxis 20 3.5.3 Non-antimicrobial
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]
  • Indirect Comparison of Efficacy Between Different Antibiotic Prophylaxis Against the Intracranial Infection After Craniotomy
    Cao et al. Antimicrobial Resistance and Infection Control (2020) 9:122 https://doi.org/10.1186/s13756-020-00784-9 RESEARCH Open Access Indirect comparison of efficacy between different antibiotic prophylaxis against the intracranial infection after craniotomy Yulong Cao1, Bin Wang2, Jiao Shan3, Zhizhong Gong4, Jiqiu Kuang1 and Yan Gao1* Abstract Background: Many studies had shown that prophylactic use of antibiotics could significantly reduce the intracranial infection (ICI) rate of craniotomy. However, there has been no comparison of these antibiotics. Methods: An electronic database search was performed, from inception to June 102,020. Randomized controlled trials (RCT) using different intravenous antibiotics (IVA) against the ICIs after craniotomy were considered. The primary outcome was the incidence rates of ICIs. An indirect treatment comparison (ITC) was conducted to compare the protective effect among the diverse antibiotic prophylaxis to prevent ICIs after craniotomy. Risk of potential bias was assessed. Results: A total of 3214 patients after craniotomy in 11 studies were included, 159 patients experienced postoperative ICI, including 33 patients in the antibacterial group and 126 in the control group. The calculate results of meta-analysis showed that except fusidic acid, preoperative intravenous injection of cephalosporin, clindamycin, vancomycin, and penicillin can significantly reduce the incidence of ICI after craniotomy, and ITC showed there was no statistically significance difference in the rates of post craniotomy ICI between the various antibiotics. Conclusion: The current evidence shows that low-grade antibacterial drugs can be selected to prevent ICI after craniotomy, but this may be due to the limited number of studies per antibiotic. It still needs more high-quality, large sample RCT to confirm.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Antibiotic Classes
    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Association of Cardiovascular Risk with Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: a Nested Case-Control Study
    Supplementary Online Content Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. Published online January 2, 2018. doi: 10.1001/jamainternmed.2017.7720 eMethods 1. Development of a disease risk score-matched nested case-control study eMethods 2. Modeling a nonlinear duration-response association using a restricted cubic splines function model. eMethods 3. A case-crossover study for assessing the association between the CVD risk and use of LABAs and LAMAs eTable 1. Diagnosis codes used to define the comorbidities and individual drugs of comedications eTable 2. Comparison of CVD risk between new LAMA use and new LABA use eTable 3. Risk of each primary cardiovascular outcome with new LABA and LAMA use eTable 4. Case-crossover analysis for the risk of CVDs with use of LABA and LAMA within 30 days eTable 5. Clinical characteristics of CVD patients during the case and control periods in an alternative case-crossover study eTable 6. Numbers needed to harm for patients who had an increased CVD risk from using LABAs and LAMAs in our primary and secondary analyses eFigure 1. Overview for the adopted nested case-control study design. CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; ER, emergency room; NHI represents National Health Insurance eFigure 2. Specification of case and control periods in an alternative case-crossover study eFigure 3. The impact of unmeasured confounders assessed by the rule-out method eFigure 4. Study flow diagram outlining the selection of study cohort © 2018 American Medical Association.
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]